Clinical trials: Positron Emission Tomography (PET)
Healthy
PET Study of Repeated ASN51 in Healthy Volunteers
This is a phase 1, open-label, dose escalation, positron emission tomography (PET) study to investigate the brain occupancy of O-GlcNAcase, and the pharmacodynamics (PD) response in peripheral blood mononuclear cells (PBMCs)…
- Trial name
- NCT05725005
- Testing
- ASN51
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Asceneuron S.A.
Primary Sjögren's Syndrome
Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome
This study consists of three consecutive parts. Part 1 in primary Sjögren's syndrome (pSS) patients (n=2-6) and Part 2 in healthy voluteers (n=3) are feasibility studies to assess if the selected [Zr-89]-rituximab PET/CT method…
- Trial name
- NCT02495129
- Testing
- VAY736 lower dose, VAY736 higher dose
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712
Determine the degree of striatal D2 receptor occupancy induced by OPC-34712 at differenht dose levels in healthy volunteers.
- Trial name
- NCT00805454
- Testing
- OPC-34712
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers
This is an open label study in 4 cohort of 4 healthy volunteers each designed to evaluate the dopamine receptor occupancy of LB-102 at various doses and timepoints.
- Trial name
- NCT04588129
- Testing
- LB-102
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- LB Pharmaceuticals Inc.
Prostate Cancer, Prostatic Neoplasms
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
- Trial name
- CLARIFY (NCT06056830)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- 34 sites in United States, Australia and 1 more
- Volunteers
- 383 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Depressive Disorder and Anxiety Disorders
First Study in Humans With GSK424887
This is the first study in Humans with GSK424887 to evaluate what effects, good or bad, the drug has on human health (safety and tolerability) and the amount of drug which gets into the bloodstream and is eliminated from the body…
- Trial name
- NCT01059591
- Testing
- GSK424887, PET
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
PCA, Prostate Cancer
PSMA PET Combined With MRI for the Detection of PCa
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection…
- Conditions
- PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET
- Trial name
- BiPASS (NCT07052214)
- Testing
- 68Ga-PSMA-11
- Where
- 18 sites in United States, Australia
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Healthy Volunteer
ENX-205 SAD/PET Study in Healthy Adults
This is a two-part study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and receptor occupancy (RO) of ENX-205 in healthy adult participants in a double-blind placebo-controlled, single ascending dose (SAD)…
- Trial name
- NCT07253246
- Testing
- ENX-205
- Where
- United Kingdom
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Engrail Therapeutics INC
Type 2 Diabetes
Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls
To evaluate 18F-AV-133 imaging of the pancreas in patients with early type 2 diabetes, late type 2 diabetes, subjects with pre-diabetes and in healthy overweight/obese control subjects.
- Trial name
- NCT01710371
- Testing
- 18F-AV-133, 10% Arginine Hydrochloride-R-Gene 10
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Healthy Volunteers
A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects
This is an open-label, single-dose study of up to 4 dose levels of ITI-333 in healthy male and female subjects. Each cohort will enroll 6 subjects.
- Trial name
- NCT05470101
- Testing
- ITI-333
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Intra-Cellular Therapies, Inc.
Colorectal Cancer, Epithelial Ovarian Cancer
[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
This is a multi-centre, open-label, single-arm, Phase 2 study designed to evaluate the diagnostic performance of [68Ga]BED003 in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC)…
- Conditions
- Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer (GC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT07702292
- Testing
- [68Ga]BED003
- Where
- 6 sites in Italy, Netherlands
- Volunteers
- 71 people
- Sponsor
- Blue Earth Diagnostics
Carcinoma, Squamous Cell of Head and Neck (HNSCC), Melanoma
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
This study is open to adults with advanced head and neck cancer, skin cancer, or non-small cell lung cancer. People can take part if previous treatments were not successful.
- Conditions
- Carcinoma, Squamous Cell of Head and Neck (HNSCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT05068102
- Testing
- BI 765063, Ezabenlimab, [89Zr]Zr- BI 765063
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
This is a phase 2, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of [18F]NAV4694 PET imaging in detecting beta-amyloid plaque in the brain in subjects with probable AD compared…
- Trial name
- NCT01680588
- Testing
- [18F]NAV4694
- Where
- 7 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Navidea Biopharmaceuticals
Alzheimer´s Disease
Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid
The study is carried out in order to investigate if [11C]AZD2995, compared to [11C]AZD2184, is a more suitable PET ligand for in vivo imaging of β amyloid depositions in the human brain.
- Trial name
- PET (NCT00692705)
- Testing
- Radioligand (11C)AZD2995, Radioligand (11C)AZD2184
- Where
- Sweden
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Amyloidosis
A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis
This study is designed to assess the repeatability of organ-specific quantitation of radiotracer uptake following Positron Emission Tomography/Computed Tomography (PET/CT) imaging of AT- 01 in subjects with amyloid light chain…
- Trial name
- AT01-001 (NCT05235269)
- Testing
- 124I-AT-01
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Attralus, Inc.
Diagnostic Imaging
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-9596 in patients with cancer and inflammation
- Trial name
- NCT01089998
- Testing
- BAY86-9596, Fludeoxyglucose (18F)-IBA
- Where
- 2 sites in Netherlands, Switzerland
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.
Neuroendocrine Tumors
A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)
The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) as a potential new way to help diagnose NETs.
- Trial name
- NCT04438304
- Testing
- 64Cu-SARTATE
- Where
- 4 sites in Australia
- Volunteers
- 45 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Alzheimer's Disease
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
This study in individuals with early Alzheimer's disease is designed to assess:(1) safety and tolerability (2) the capacity of ACC-001 and QS-21 adjuvant to reduce brain amyloid load as measured by positron emission tomography…
- Trial name
- NCT01227564
- Testing
- ACC-001 3 μg/ QS-21 50 μg, ACC-001 10 μg/ QS-21 50 μg
- Where
- 40 sites in United States
- Volunteers
- 63 people
- Sponsor
- Pfizer
Liver Metastases, Colorectal Carcinoma
An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.
Estimation of the concordance of Tc 99m localization in liver metastases from colorectal carcinoma using SPECT/CT imaging and abdominal FDG (PET)/CT imaging per subject.
- Trial name
- NCT03029988
- Testing
- Tilmanocept (Technetium Tc 99m tilmanocept Injection), SPECT/CT Imaging
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Navidea Biopharmaceuticals
Healthy
Suitability of 11C-ORM-13070 as a PET Tracer
The purpose of the study is to evaluate the suitability of 11C-ORM-13070 as a positron emission tomography tracer.
- Trial name
- NCT00735774
- Testing
- 11C-ORM-13070
- Where
- Finland
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma